A new type of norovirus is causing a very high number of cases in countries like England, just as a large trial of an mRNA ...

Researchers developing Australia’s first mRNA Covid vaccine say they may have solved the one of the biggest problems with ...

As scientists look to model every aspect of mRNA processing, publicly available data on tangential flow filtration (TFF) is ...

Researchers developing Australia’s first mRNA Covid vaccine say they may have solved the “immune imprinting” issue that has ...

Penn Engineers have modified lipid nanoparticles (LNPs)—the revolutionary technology behind the COVID-19 mRNA vaccines—to not ...

As human cases of avian influenza slowly tick up amid the outbreak in U.S. dairy cattle, the Centers for Disease Control and ...

Hope for a much-needed treatment for the common pregnancy complication pre-eclampsia has been raised by a successful test of ...

A new mRNA therapy tested in mice may target the root cause of the potentially fatal pregnancy disorder preeclampsia. It's ...

Fintel reports that on December 18, 2024, Argus Research downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 10.82% ...

Europe has approved two drugs for preventing COVID-19 infection: a monoclonal antibody and a self-amplifying mRNA vaccine.

Engineers have modified lipid nanoparticles (LNPs) -- the revolutionary technology behind the COVID-19 mRNA vaccines -- to not only cross the blood-brain barrier (BBB) but also to target specific ...